You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

trametinib

( tra-MET-i-nib )
Funding:
Exceptional Access Program
  • trametinib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
  • trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Other Name(s): Mekinist®
Appearance: tablet In various strengths, shapes and colours

Patient Info Sheet

Aug 2018

What it is used for

  • For treating a specific type of skin cancer called melanoma or lung cancer (non-small cell) that has spread to other parts of the body or cannot be removed by surgery.
     
  • Trametinib may be given alone, or together with another medication called dabrafenib.


You might also be interested in